|   | 
        
            
         | 
          | 
        
        
        
            | 
                
             | 
         
        
             | 
         
        
            
            
            
  
    
	  | 
   
  
    
        
          |   | 
          
              
                | 
                    °ÇÀÏÆç·ÎµðÇÉÁ¤5mg  Kuhnil Felodipine Tab. 5mg  
                    
                 | 
               
              
                
                     Àü¹®ÀǾàǰ | »èÁ¦  
                         |  
                    
                    	
                    
                 | 
               
              
                | 
					  
                  
				  
                 | 
               
              
              
              
              
              |   |  
              
                
                    
                        | 
                      ¾Ë¸²:  | 
                      µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. | 
                     
                    | 
               
            
              
                
                   
                   
                   
                   
		   
                 | 
               
              
                | 
                  
                  
                 | 
               
              | 
            | 
         
       
       | 
   
    |  
  
    | 
      
     | 
     
  |  
                              
                                  | 
                                   | 
                               
            
            
                
            
            
              
            
                            
              
                                                     
            
            
   |  
  
    | 
      
     | 
   
   
     | 
   
    
   
    | 
       
        À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
        ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
        À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
        ·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
       
     | 
   
  
     | 
   
   
  
    
      
	
	  
	     |  
	    
	      
	        
            
                | Çã°¡Á¤º¸ | 
                         
	         
	       | 
	     
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå  »óÇÑ±Ý¾× | 
    
      
      
        
        646800460[A03805691]  
	    
	    Àú°¡¾à ´ëü Àμ¾Æ¼ºê Áö±Þ ´ë»ó
          [º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸] 
          
        
        
        
          
          
            \0 ¿ø/1Á¤(2020.02.01)(ÇöÀç¾à°¡) 
            \367 ¿ø/1Á¤(2017.02.01)(º¯°æÀü¾à°¡)
        
          
            
	 
  	   
  	   
       
      
       
       
     
      
      
     
      
    
    
      
     [»óº´ÄÚµåÁ¶È¸]
      
     [Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
     [¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
     | 
   
   
    | ºü¸¥Á¶È¸ | 
    
      
     |   
   
  
  
   
    | Á¦Ç°¼º»ó | 
    
      ¿¬ºÐÈ«»öÀÇ ¿øÇü Çʸ§ÄÚÆÃÁ¤  
      
	    [Á¦ÇüÁ¤º¸ È®ÀÎ]
     |   
   
  
  
  
  
  
   
    | Æ÷À塤À¯Åë´ÜÀ§ | 
    ÀÚ»çÆ÷Àå´ÜÀ§¿¡ µû¸§ | 
   
  
  
  
   
    | Æ÷À塤ÄÚµå´ÜÀ§ | 
    
        
        
            | ¾àǰ±Ô°Ý | 
            ´ÜÀ§ | 
            ´ëÇ¥ÄÚµå | 
            Ç¥ÁØÄÚµå | 
            ºñ°í | 
	     
        
        
            | 5¹Ð¸®±×·¥ | 
            100 Á¤ | 
            8806468004602 | 
            8806468004626 | 
             | 
	     
        
        
            | 5¹Ð¸®±×·¥ | 
            30 Á¤ | 
            8806468004602 | 
            8806468004619 | 
             | 
	     
        
         
     | 
   
      
  
  	
   
    | ÁÖ¼ººÐÄÚµå | 
    
      157501ATR  
      
	  [µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
     | 
   
  
  
  
  
  	
   
    | ´ëÇ¥ÄÚµå | 
    8806468004602 | 
   
  
  
  
  
   
    | º¸°ü¹æ¹ý | 
    Â÷±¤ÇÑ ±â¹Ð¿ë±â, ½Ç¿Â(1-30¡É)º¸°ü | 
   
  
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
      
        [Á¶È¸]
     | 
      
  
  
  
  
   
    | È¿´ÉÈ¿°ú | 
    
    [ÀûÀÀÁõ º° °Ë»ö] 
      
    
     
	 
      °íÇ÷¾Ð, ¾ÈÁ¤Çü Çù½ÉÁõ
      
      
      
      
     | 
   
  
  
  
  
  
   
    | 1ÀÏ ÃÖ´ë Åõ¿©·® | 
    
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
       
     | 
      
  
  
  
  
    
  
  
   
    | ¿ë¹ý¿ë·® | 
    
      * Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù. 
    
     
      
      
     [󹿾à¾î] 
      ÀÌ ¾àÀ» º¹¿ë½Ã ¹°°ú ÇÔ²² ±×´ë·Î »ïÄÑ¾ß ÇÏ¸ç ºÐÇÒÇϰųª ¾Ã°Å³ª ºÎ¼ö¾î¼ º¹¿ëÇÏÁö ¾Ê´Â´Ù.   
  
¡Û ¼ºÀÎ  
  
1. °íÇ÷¾Ð  
 Æç·ÎµðÇÉÀ¸·Î¼ ÃÊȸ·®À¸·Î 1ÀÏ 1ȸ 5§·À», À¯Áö·®À¸·Î 1ÀÏ 5‐10§·À» ¾ÆÄ§¿¡ °æ±¸Åõ¿©ÇÑ´Ù. 1ÀÏ ÃÖ´ë 20§·À» ÃʰúÇÏÁö ¾Ê´Â´Ù. ÀÌ ¾àÀº ¥â‐Â÷´ÜÁ¦ ¶Ç´Â ÀÌ´¢Á¦¿Í º´¿ëÅõ¿©ÇÒ ¼ö ÀÖÀ¸¸ç ´Ù¸¥ Ç÷¾Ð°ÇÏÁ¦°¡ ºÎÀûÀýÇÑ °æ¿ì¿¡´Â ÀÌ ¾à ´Üµ¶¿ä¹ýÀ¸·Î¼ Åõ¿©ÇÒ ¼ö ÀÖ´Ù.  Åõ¿©¿ë·®Àº ȯÀÚÀÇ Ä¡·á¹ÝÀÀ¿¡ µû¶ó Á¶ÀýÇÑ´Ù.   
2.¾ÈÁ¤Çü Çù½ÉÁõ   
ÃÊȸ·®À¸·Î 1ÀÏ 1ȸ 5§·À» Åõ¿©Çϸç Çʿ信 µû¶ó 10§·À¸·Î Áõ·®ÇÒ ¼ö ÀÖ´Ù.ÀÌ ¾àÀº ¥â‐Â÷´ÜÁ¦¿¡ ÀÇÇÏ¿© ÃæºÐÇÑ È¿°ú°¡ ³ªÅ¸³ªÁö ¾Ê´Â °æ¿ì¿¡ º´¿ëÅõ¿©ÇÒ ¼ö ÀÖ´Ù.  Åõ¿©¿ë·®Àº ȯÀÚÀÇ Ä¡·á¹ÝÀÀ¿¡ µû¶ó Á¶ÀýÇÑ´Ù.   
3. °í·ÉÀÚ 
ÃÊȸ·®À¸·Î 1ÀÏ 2.5§·À» Åõ¿©ÇÏ´Â °ÍÀ» °í·ÁÇÏ´Â µî ȯÀÚÀÇ »óŸ¦ °üÂûÇÏ¸é¼ ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
  
4. ½ÅÀå¾Ö ȯÀÚ 
½ÅÀå¾Ö´Â Æç·ÎµðÇÉÀÇ Ç÷Áß ³óµµ¿¡ ¿µÇâÀ» ÁÖÁö ¾Ê´Â´Ù. ¿ë·® Á¶ÀýÀº ÇÊ¿äÇÏÁö ¾ÊÁö¸¸ ÁßÁõÀÇ ½ÅÀå¾Ö ȯÀÚ(CFR<30ml/min)´Â ½ÅÁßÈ÷ Åõ¿©ÇØ¾ß ÇÑ´Ù.
  
5. °£Àå¾Ö ȯÀÚ 
°£Àå¾Ö ȯÀÚ´Â Æç·ÎµðÇÉÀÇ Ç÷Áß ³óµµ°¡ Áõ°¡ÇÒ ¼ö ÀÖÀ¸¸ç, ´õ ³·Àº ¿ë·®¿¡¼ Ä¡·á¿¡ ¹ÝÀÀÇÒ ¼ö ÀÖ´Ù. µû¶ó¼ ÃÊȸ·®À¸·Î 1ÀÏ 2.5mgÀ» Åõ¿©ÇÏ´Â °ÍÀ» °í·ÁÇÏ´Â µî °£±â´ÉÀå¾Ö ȯÀÚ´Â ½ÅÁßÈ÷ Åõ¿©ÇØ¾ß Çϸç, ÁßÁõÀÇ °£±â´ÉÀå¾Ö ȯÀÚ´Â Åõ¿©Çؼ´Â ¾È µÈ´Ù.
  
6. ¼Ò¾Æ 
¼Ò¾Æ¿¡ ´ëÇÑ ¾ÈÀü¼º ¹× À¯È¿¼ºÀÌ È®¸³µÇ¾î ÀÖÁö ¾Ê´Ù.      
      	    
     | 
   
  
  
  
   
    | ÁÖ¿ä¾à¹° »óÈ£ÀÛ¿ë | 
    
        
	  [º¸±â]
     | 
   
  
  
  
  
  
  
  
   
    | ±Ý±â | 
    
      1) ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀÎ 
2) ½ÉÀμº ¼ï ȯÀÚ(ÀúÇ÷¾Ð¿¡ ÀÇÇØ Áõ»óÀÌ ¾Ç鵃 ¼ö ÀÖ´Ù.) 
3) ÀÌ ¾à¿¡ °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ 
4) ´ëµ¿¸ÆÆÇ.½Â¸ðÆÇÇùÂøÁõ ȯÀÚ(Ç÷°üÈ®ÀåÀÛ¿ë¿¡ ÀÇÇØ °úµµ  ÇÑ Ç÷¾Ð°Çϰ¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.) 
5) ÁßÁõÀÇ °£±â´ÉÀå¾Ö ȯÀÚ 
6) ½ÉÀå´ë»ó(ÓÛßÁ)±â´ÉºÎÀü ȯÀÚ 
7) ±Þ¼º ½É±Ù°æ»ö ȯÀÚ 
8) ºÒ¾ÈÁ¤¼º Çù½ÉÁõ ȯÀÚ 
9) ÀÌ ¾àÀº À¯´çÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î, °¥¶ôÅä¿À½º ºÒ³»¼º(galactose intolerance), Lapp À¯´çºÐÇØÈ¿¼Ò °áÇÌÁõ(Lapp lactase deficiency) ¶Ç´Â Æ÷µµ´ç-°¥¶ôÅä¿À½º Èí¼öÀå¾Ö(glucose-galactose malabsorption) µîÀÇ À¯ÀüÀûÀÎ ¹®Á¦°¡ Àִ ȯÀÚ¿¡°Ô´Â Åõ¿©ÇÏ¸é ¾È µÈ´Ù.(À¯´çÇÔÀ¯ Á¦Á¦¿¡ ÇÑÇÔ)
  
     | 
   
  
  
  
  
   
    | ½ÅÁßÅõ¿© | 
    1) °í·ÉÀÚ(°úµµÇÑ Ç÷¾Ð°ÇÏ¿¡ ÀÇÇÏ¿© ³ú°æ»öÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.) 
2) ½ÉºÎÀü ȯÀÚ 
3) ÀúÇ÷¾Ð ȯÀÚ 
4) °£±â´ÉÀå¾Ö ȯÀÚ 
5) ÁßÁõÀÇ ½ÅºÎÀü ȯÀÚ(CFR<30ml/min)
 
  | 
   
  
  
  
   
    | ÀÌ»ó¹ÝÀÀ | 
    
      ´Ù¸¥ ¼¼µ¿¸Æ È®ÀåÁ¦µé°ú ¸¶Âù°¡Áö·Î ÀÌ ¾àÀ» óÀ½ Åõ¿©ÇϰŠ ³ª ¿ë·®À» Áõ°¡½ÃŰ´Â °æ¿ì¿¡ ¾È¸éÈ«Á¶, µÎÅë, ½É°èÇ×Áø, Çö±âÁõ, ÇǷΰ¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ÀÌµé ´ëºÎºÐÀº ¿ë·® ÀÇÁ¸ÀûÀ̰í ÀϽÃÀûÀ̾ú´Ù. ÀÓ»ó½ÃÇè°ú ½ÃÆÇÈÄ Á¶»ç¿¡¼ º¸°íµÈ ºÎÀÛ¿ëµéÀº ´ÙÀ½°ú °°´Ù.
  
1) ¼øÈ¯±â°è : ¶§¶§·Î ½É°èÇ×Áø, ºó¸Æ, ¼û¸·Èù°¨, ÈäºÎ¾Ð¹Ú°¨ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç, ÀÌ ¾àÀÇ Åõ¿©·®°ú °ü·ÃÇÏ¿© Àü¸ð¼¼Ç÷°ü(precapillary)È®Àå¿¡ ÀÇÇÏ¿© ¹ß¸ñºÎÁ¾ÀÌ ÀÚÁÖ ³ªÅ¸³¯ ¼ö ÀÖÀ¸³ª Àü½ÅÀû ü¾×Àú·ù¿¡ °ü°èµÈ °ÍÀº ¾Æ´Ï´Ù. ¶ÇÇÑ ¹Î°¨ÇÑ È¯ÀÚÀÇ °æ¿ì¿¡´Â ¸Å¿ì µå¹°°Ô Çù½ÉÁõÀ» ÀÏÀ¸Å°´Â ºó¸ÆÀ» ¼ö¹ÝÇÑ ÀúÇ÷¾Ð, ±â¿Ü¼öÃàÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.  
2) Á¤½Å½Å°æ°è : ÀÚÁÖ µÎÅëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ¶§¶§·Î µÎÁß°¨, ¾îÁö·¯¿ò, ºñƲ°Å¸², ±Çۨ, Á¹À½, ÃÊÁ¶°¨, ÇÇ·Î, °¨°¢ÀÌ»ó µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. µå¹°°Ô ÀúÇ÷¾Ð¿¡ ÀÇÇÑ ½Ç½ÅÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù.  
3) ¼Òȱâ°è : ¶§¶§·Î ±¸¿ª, º¯ºñ, À§ºÎºÒÄè°¨, °¡½¿ ¾²¸², º¹Åë, ½Ä¿åºÎÁø, ¼³»ç, ±¸°¥ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. µå¹°°Ô ±¸Åä°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. 
4) ±¸° : ÇöÀúÇÑ Ä¡Àº¿°/Ä¡±Ù¸·¿° ȯÀÚÀÇ °æ¿ì¿¡´Â ÀÌ ¾à Åõ¿©ÈÄ Ä¡ÀººñÈÄÁõ»óÀÌ ³ªÅ¸³µ´Ù´Â º¸°í°¡ ÀÖÀ¸³ª ÀÌ·¯ÇÑ Áõ»óÀº Ä¡¾ÆÀ§»ý¿¡ ÁÖÀÇÇÔÀ¸·Î½á ÁÙÀ̰ųª ÇÇÇÒ ¼ö ÀÖ´Ù. ¸Å¿ì µå¹°°Ô Ä¡ÀººñÈÄÁõ»ó, Ä¡Àº¿°ÀÌ ³ªÅ¸³µ´Ù. 
5) °£Àå : ¸Å¿ì µå¹°°Ô AST, ALT, ALP, LDH µîÀÇ »ó½ÂÀÌ ³ªÅ¸³µ´Ù´Â º¸°í°¡ ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇϰí ÀÌ»óÀÌ ÀÎÁ¤µÇ´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù. 
6) ½ÅÀå : ¶§¶§·Î BUN.Å©·¹¾ÆÆ¼´ÑÀÇ »ó½Â µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. 
7) Ç÷¾× : ¶§¶§·Î ºóÇ÷ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇϰí ÀÌ»óÀÌ ÀÎÁ¤µÇ´Â °æ¿ì¿¡´Â °¨·® ¶Ç´Â Åõ¿©¸¦ Áß´ÜÇÏ´Â µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù. 
8) ÇǺΠ: ÀÚÁÖ ¿À» ¼ö¹ÝÇÏ´Â ¾È¸éÈ«Á¶, ¶§¶§·Î ¹ßÁø, °¡·Á¿ò, ¹Ú¸®¼º ÇǺο°, ÇǺΠȫÅëÁõ, µå¹°°Ô µÎµå·¯±â µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù. ¸Å¿ì µå¹°°Ô ±¤°ú¹Î¼º ¹ÝÀÀ, ÀÔ¼úÀ̳ª Çô°¡ ºÎ¾î¿À¸£´Â ¸Æ°üºÎÁ¾ ¹× ¹éÇ÷±¸ ÆÄ¼â¼º Ç÷°ü¿°ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.  
9) ±Ù°ñ°Ý°è: µå¹°°Ô ±ÙÀ°Åë, °üÀýÅëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.  
10) ³»ºÐºñ°è: ¸Å¿ì µå¹°°Ô °íÇ÷´çÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.  
11) ±âŸ : üÁßÁõ°¡, ¶§¶§·Î ¸»Ãʼº ºÎÁ¾, ´Ù¸®°æ·Ã, ¾î±ú°á¸², ¹«·Â°¨, ÇÇ·Î, ¼öÁöÁøÀü, ±âħ, ÀÎÈÄÀ§È°¨, ¹ßÇÑ, ´«¹°, ¾È±¸ÃæÇ÷, Âø°¨°¢Áõ, CPK¡¤ÃÑÄÝ·¹½ºÅ×·Ñ¡¤Æ®¸®±Û¸®¼¼¶óÀ̵åÀÇ »ó½Â, Ç÷ûĮ·ýÀÇ ÀúÇÏ, µå¹°°Ô ¿©¼ºÇü À¯¹æ, ¹ß±âºÎÀü, ¼º±â´ÉÀå¾Ö°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ¸Å¿ì µå¹°°Ô ºó´¢, Ç÷°üºÎÁ¾, ¹ß¿°ú °°Àº °ú¹Î¹ÝÀÀÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. È¥µ·, ¼ö¸éÀå¾Ö°¡ º¸°íµÇ¾úÀ¸³ª º»Á¦¿ÍÀÇ ¿¬°ü¼ºÀº È®¸³µÇÁö ¾Ê¾Ò´Ù. °íÇ÷´çÀº ÀÌ °è¿ÀÇ ¾à¹°¿¡¼ ³ªÅ¸³ª´Â ºÎÀÛ¿ëÀÌ¸ç º» Á¦ÀÇ °æ¿ì ¸Å¿ì µå¹°°Ô °íÇ÷´çÀÌ º¸°íµÇ¾ú´Ù. °í·ÉÀÚ ¹× °£¼Õ»ó ȯÀÚÀÇ °æ¿ì 1ÀÏ 2.5mgÀ¸·Î ÃæºÐÇϸç, 1ÀÏ 10mg Ãʰú·®Àº ´ëü·Î ÇÊ¿äÇÏÁö ¾Ê´Ù.
          
     | 
   
  
  
    
   
    | ÀϹÝÀû ÁÖÀÇ | 
    1) Ä®½·±æÇ×Á¦ÀÇ Åõ¿©¸¦ °©ÀÚ±â ÁßÁöÇÏ´Â °æ¿ì¿¡´Â Áõ»óÀÌ  ¾ÇȵǾú´Ù´Â º¸°í°¡ ÀÖÀ¸¹Ç·Î ÀÌ ¾àÀÇ Åõ¿©¸¦ ÁßÁöÇÏ´Â °æ¿ì¿¡´Â õõÈ÷ °¨·®Çϰí ÃæºÐÈ÷ °üÂûÇÑ´Ù. ¶ÇÇÑ È¯ÀÚ¿¡°Ô ÀÇ»çÀÇ Áö½Ã ¾øÀÌ Åõ¿©¸¦ ÁßÁöÇÏÁö ¾Êµµ·Ï ÁÖÀÇÇÑ´Ù. 
2) µå¹°°Ô °úµµÇÑ Ç÷¾Ð°Çϰ¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì¿¡´Â °¨·® ¶Ç´Â Åõ¿©¸¦ Áß´ÜÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù. 
3) Ç÷¾Ð°ÇÏÀÛ¿ë¿¡ ÀÇÇØ ¾îÁö·¯¿òÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î °í¼ÒÀÛ¾÷À̳ª ÀÚµ¿Â÷¿îÀü µî À§ÇèÀÌ ¼ö¹ÝµÇ´Â ±â°èÁ¶ÀÛÀ» ÇÏÁö ¾Êµµ·Ï ÁÖÀÇÇÑ´Ù. 
4) ÀÌ ¾àÀº ¾ÆÄ§¿¡ º¹¿ëÇÏ¿©¾ß ÇÑ´Ù. ÀÌ ¾àÀº °øº¹¿¡ º¹¿ë Çϰųª Áö¹æ, ´Ù·®ÀÇ Åº¼öȹ°À» ÇÔÀ¯ÇÏÁö ¾ÊÀº °¡º¿î ½Ä»ç ÈÄ º¹¿ëÇÒ ¼ö ÀÖ´Ù.
 
  | 
   
  
  
  
    
   
    | »óÈ£ÀÛ¿ë | 
    ÀÌ ¾àÀº CYP3A4ÀÇ ±âÁúÀÌ´Ù. CYP3A4¸¦ ÀúÇØÇϰųª À¯µµÇÏ´Â ¾àÁ¦´Â ÀÌ ¾àÀÇ Ç÷Àå ³óµµ¿¡ À¯ÀÇÇÑ ¿µÇâÀ» ÁֹǷΠº´¿ëÅõ¿©¸¦ ÇÇÇϵµ·Ï ÇÑ´Ù.
  
1) ´Ù¸¥ Ç÷¾Ð°ÇÏÁ¦¿Í º´¿ë Åõ¿©ÇÏ´Â °æ¿ì¿¡´Â »óÈ£ÀÛ¿ëÀÌ Áõ°¡µÉ ¼ö ÀÖÀ¸¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. 
2) ¸ÞÅäÇÁ·Î·ÑÀ» º´¿ë Åõ¿©ÇÏ´Â °æ¿ì¿¡´Â ¸ÞÅäÇÁ·Î·ÑÀÇ Ç÷Áß³óµµ°¡ »ó½ÂµÉ ¼ö ÀÖ´Ù. 
3) µð°î½Å°ú º´¿ë Åõ¿©ÇÏ´Â °æ¿ì¿¡´Â µð°î½ÅÀÇ Ç÷Àå³óµµ°¡ »ó½ÂµÉ ¼ö ÀÖ´Ù. 
4) ¿¡¸®½º·Î¸¶À̽Å, ÀÌÆ®¶óÄÚ³ªÁ¹, ÄÉÅäÄÚ³ªÁ¹, HIV ÇÁ·ÎÅ×¾ÆÁ¦ ÀúÇØÁ¦µîÀÇ °·ÂÇÑ CYP3A4 ÀúÇØÁ¦¿Í º´¿ëÅõ¿©´Â ÇÇÇÏ´Â °ÍÀÌ ÁÁ´Ù. ÀÌÆ®¶óÄÚ³ªÁ¹ÀÇ °æ¿ì ÀÌ ¾àÀÇ Cmax°¡ 8¹è, AUC°¡ 6¹è Áõ°¡ÇÏ¿© ¾à¹°ÀÇ ÀÌ»ó¹ÝÀÀ(¿¹ : ´Ù¸®ºÎÁ¾) ¹ßÇöÀ²À» Áõ°¡½ÃŲ´Ù. ¿¡¸®½º·Î¸¶À̽Űú º´¿ëÅõ¿©½Ã Æç·ÎµðÇÉÀÇ Cmax¿Í AUC´Â ¾à 2.5¹è Áõ°¡ÇÑ´Ù.  
5) ½Ã¸ÞƼµò°ú º´¿ëÅõ¿©ÇÏ´Â °æ¿ì, Æç·ÎµðÇÉÀÇ Cmax¿Í AUC°¡ ¾à 55% Áõ°¡Çß´Ù.  
6) Æä´ÏÅäÀÎ, Ä«¸£¹Ù¸¶Á¦ÇÉ, ¸®ÆÊÇǽÅ, Æä³ë¹Ù¸£ºñÅ» ¹× ¼¼ÀÎÆ® Á¸½º ¿ÍÆ®¿Í °°Àº È¿¼Ò (½ÃÅäÅ©·Ò P450)À¯µµ¾à¹°°ú º´¿ëÅõ¿©ÇÏ´Â °æ¿ì¿¡´Â ÀÌ ¾àÀÇ ´ë»ç°¡ Áõ°¡µÇ¾î Ç÷Àå³óµµ¸¦ °¨¼Ò½Ãų ¼ö ÀÖ´Ù. Ä«¹Ù¸¶Á¦ÇÉ, Æä´ÏÅäÀÎ ¹× Æä³ë¹Ù¸£ºñÅ»°ú ÀÌ ¾àÀ» º´¿ëÅõ¿©½Ã ÀÌ ¾àÀÇ AUC´Â 93%, Cmax´Â 82% °¨¼ÒÇß´Ù. CYP3A4 À¯µµÁ¦¿Í º´¿ëÇÏÁö ¾Êµµ·Ï ÇÑ´Ù.  
7) ¸®ÆÊÇǽŰú º´¿ëÅõ¿©ÇÏ´Â °æ¿ì¿¡´Â ´Ù¸¥ Ä®½·±æÇ×Á¦(´ÏÆäµðÇÉ µî)ÀÇ ÀÛ¿ëÀ» °¨¼Ò½ÃÄ×´Ù´Â º¸°í°¡ ÀÖÀ¸¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. 
8) »çÀÌÅäÅ©·Ò P-450 3A4 È¿¼Ò¸¦ ¹æÇØÇÏ´Â ¾à¹°°ú º´¿ëÅõ¿©ÇÏ´Â °æ¿ì¿¡´Â ÀÌ ¾àÀÇ ÀÛ¿ëÀÌ Áõ°¡µÉ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ ¾àÀÇ ¿ë·®À» °¨·®ÇÏ´Â µî ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. 
9) ÀÌ ¾à°ú ÀÚ¸ù(grapefruit)ÁÖ½º¿Í ÇÔ²² Åõ¿©ÇÏ´Â °æ¿ì¿¡´Â ÀÌ ¾à°ú ÁÖ½ºÀÇ Çö󺸳ëÀÌµå ¼ººÐ°úÀÇ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ Cmax¿Í AUC°¡ µÎ ¹è Áõ°¡Çß´Ù. µû¶ó¼ ÀÌ ¾à°ú ÀÚ¸ù ÁÖ½º¸¦ ÇÔ²² º¹¿ëÇÏÁö ¾Ê´Â´Ù. 
10) »çÀÌŬ·Î½ºÆ÷¸°°ú º´¿ëÅõ¿©ÇÏ´Â °æ¿ì¿¡´Â ¿î¹Ý È¿¼Ò P-glycoproteinÀ» ÀúÇØÇϹǷΠÀÌ ¾àÀÇ Ç÷Àå ³óµµ°¡ Áõ°¡ÇÑ´Ù. Cmax´Â 150%±îÁö Áõ°¡Çϰí AUC´Â 60% Áõ°¡ÇÑ´Ù. ÀÌ ¾àÀÌ »çÀÌŬ·Î½ºÆ÷¸°ÀÇ ¾àµ¿Çп¡ ¹ÌÄ¡´Â ¿µÇâÀº Å©Áö ¾Ê´Ù. 
11) ÀÌ ¾àÀÇ Ç÷Àå ´Ü¹é °áÇÕ·üÀº ³ôÀ¸³ª ¿ÍÆÄ¸°°ú °°ÀÌ ±¤¹üÀ§ÇÏ°Ô °áÇÕÇÏ´Â ´Ù¸¥ ¾à¹°ÀÇ ¹Ì°áÇÕ ºÐȹ¿¡´Â ¿µÇâÀ» ¹ÌÄ¡Áö ¾Ê´Â °ÍÀ¸·Î º¸ÀδÙ. 
12) ÀÌ ¾àÀº Ÿũ·Î¸®¹«½ºÀÇ ³óµµ¸¦ ³ôÀÏ ¼ö ÀÖ´Ù. µÎ ¾àÀ» º´¿ë½Ã tacrolimusÀÇ Ç÷û ³óµµ¸¦ ¸ð´ÏÅÍÇÏ¿© ¿ë·®À» Á¶ÀýÇÑ´Ù.
 
  | 
   
  
  
  
   
    | ÀӺο¡ ´ëÇÑ Åõ¿© | 
    
      
	[ÀӺαݱ⠼ººÐ Á¶È¸]       
      1) µ¿¹°½ÇÇèÀÇ »ý½Ä°úÁ¤¿¡¼ ÅÂÀÚ¼Õ»óÀ̳ª ±âŸ À¯ÇØ ÀÛ¿ëÀÇ ¹ß»ýÀ» Áõ°¡½ÃÄ×´Ù´Â º¸°í°¡ ÀÖÀ¸³ª »ç¶÷¿¡ °üÇÑ À¯ÀǼºÀº ¸íÈ®ÇÏÁö ¾Ê´Ù. 
2) µ¿¹°½ÇÇè(Åä³¢)¿¡¼ ÀÌ ¾àÀÇ Åõ¿©¿ë·®°ú °ü·ÃÇÏ¿© ¾ÏÄÆ Åä³¢ÀÇ À¯¼±(mammary gland)À» °¡¿ªÀûÀ¸·Î È®Àå½Ã۰í ÅÂÀÚ¹ßÀ°ÀÇ Ãʱâ´Ü°è¿¡¼ ÅÂÀÚÀÇ ¸»´ÜÁöÀý(distalphalanges)¿¡ ºñÁ¤»óÀûÀÎ °á°ú°¡ ³ªÅ¸³µ´Ù´Â º¸°í°¡ ÀÖ´Ù. 
3) ·§Æ®¿¡ ´ëÇÑ ¼öÅ ¹× »ý½Ä½ÃÇè¿¡¼ Åõ¿©¿ë·®°ú ¿¬°üÇÏ¿© ºÐ¸¸°úÁ¤À» ¾ÇȽÃÄÑ ºÐ¸¸Áö¿¬, ÅÂÀÚ ¹× ½Å»ýÀÚÀÇ »ç¸Á·ü Áõ°¡°¡ ³ªÅ¸³µ´Ù´Â º¸°í°¡ ÀÖ´Ù. 
4) ÀӺο¡ ´ëÇÑ ¾ÈÀü¼ºÀÌ ¾ÆÁ÷ È®¸³µÇ¾î ÀÖÁö ¾ÊÀ¸¹Ç·Î ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀο¡´Â Åõ¿©ÇÏÁö ¾Ê´Â´Ù. 
5) Ä®½·±æÇ×Á¦´Â ÀÚ±ÃÀÇ Á¶±â ¼öÃàÀ» ÀúÇØÇÒ ¼ö ÀÖ´Ù. ºÐ¸¸ÀÌ Áö¿¬µÈ´Ù´Â Áõ°Å´Â ¾ø´Ù. »ê¸ð ÀúÇ÷¾Ð ¹× ¸»ÃÊÇ÷°üÈ®ÀåÀ¸·Î ÀÎÇÑ Ç÷·ùÀÇ Àç¹èÄ¡·Î ÀÎÇØ Àڱà °ü·ù°¡ °¨¼ÒµÈ °æ¿ì žÆÀú»ê¼ÒÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. 
  
     | 
   
  
  
  
  
   
    | ¼öÀ¯ºÎ¿¡ ´ëÇÑ Åõ¿© | 
    µ¿¹°½ÇÇè¿¡¼ ¸ðÀ¯ ÁßÀ¸·ÎÀÇ ÀÌÇàÀÌ º¸°íµÇ¾î ÀÖÀ¸¹Ç·Î ¼öÀ¯Áß¿¡´Â Åõ¿©¸¦ ÇÇÇÏ°í ºÎµæÀÌÇÑ °æ¿ì¿¡´Â ¼öÀ¯¸¦ Áß´ÜÇÑ´Ù.
 
  | 
   
  
  
  
  
   
    | ¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿© | 
    
      
       
      ¼Ò¾Æ¿¡ ´ëÇÑ ¾ÈÀü¼ºÀÌ È®¸³µÇ¾î ÀÖÁö ¾Ê´Ù(»ç¿ë°æÇèÀÌ ¾ø´Ù.). 
 | 
   
  
  
  
   
    | °í·ÉÀÚ¿¡ ´ëÇÑ Åõ¿© | 
    
      ÀϹÝÀûÀ¸·Î °í·ÉÀÚ¿¡¼ÀÇ °úµµÇÑ Ç÷¾Ð°ÇÏ´Â ¹Ù¶÷Á÷ÇÏÁö ¾ÊÀ¸¹Ç·Î(³ú°æ»ö µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.) Àú¿ë·®(1ÀÏ 1ȸ 2.5§·)¿¡¼ Åõ¿©¸¦ ½ÃÀÛÇÏ´Â µî ȯÀÚÀÇ »óŸ¦ °üÂûÇÏ¸é¼ ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. | 
   
  
  
  
  
  
  
  
  
  
  
  
  
   
    | °ú·®Åõ¿© ¹× óġ | 
    µ¶¼º: 10mgÀ» 2¼¼ À¯¾Æ¿¡°Ô Åõ¿©½Ã °æÁõÀÇ Áßµ¶ Áõ»óÀ» ÀÏÀ¸Ä×´Ù. 150~200mgÀÌ 17¼¼ û¼Ò³â¿¡°Ô, 250mgÀÌ ¼ºÀο¡°Ô °æ•ÁߵÀÇ Áßµ¶À» ÀÏÀ¸Ä×À¸¸ç, ´Ù¸¥ Ä®½·±æÇ×Á¦¿Í ºñ±³ÇßÀ» ¶§ Æç·ÎµðÇÉÀº ½ÉÀ庸´Ù´Â ¸»ÃʼøÈ¯¿¡ ´õ ¿µÇâÀ» ¹ÌÄ£´Ù.    
Áõ»ó: Áßµ¶ÀÇ Áõ»óÀº 12~16½Ã°£ Áö¿¬µÉ ¼ö ÀÖÀ¸¸ç, ¾ÇÈµÈ Áõ»óÀÌ ¸çÄ¥ ÈÄ¿¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. Áß¿äÇÏ°Ô ³ªÅ¸³ª´Â ½ÉÇ÷°ü°è Áõ»óÀ¸·Î, Ç÷¾ÐÀÌ ÇöÀúÈ÷ ³·¾ÆÁö°Å³ª, ¼¸Æ(¶§·Î ºó¸Æ), ¹æ½ÇÂ÷´Ü I-III, ¹æ½ÇºÐ¸®, ½É½Ç¼º ±â¿Ü¼öÃà, ºÎÀü¼öÃàÀÌ ÀÖ´Ù. Çö±âÁõ, µÎÅë, Àǽļջó, È¥¼ö, °æ·Ã, È£Èí°ï¶õ, ÆóºÎÁ¾(½ÉºÎÁ¾ÀÌ ¾Æ´Ô), ¹«È£Èí, ¼ºÀμº È£Èí°ï¶õÁõ, »êÁõ, ÀúÄ®·ýÇ÷Áõ, °íÇ÷´ç, ÀáÀçÀû ÀúÄ®½·Ç÷Áõ, ¾È¸éÈ«Á¶, Àúü¿ÂÁõ, ¿À½É, ±¸Åä Áõ»óÀÌ ³ªÅ¸³´Ù. 
  
óġ: ÇÊ¿äÇÑ °æ¿ì ÀûÀýÇÒ ¶§ ÃÖÅäÇϰųª ¾à¿ëźÀ¸·Î À§¼¼Ã´À» Çϸç, ´ëÁõ¿ä¹ýÀ¸·Î óġÇÑ´Ù. ¹ÌÁֽŰæ ÀÚ±ØÀÇ À§Ç輺¶§¹®¿¡ À§¼¼Ã´ Àü¿¡ ¾ÆÆ®·ÎÇÉ(¼ºÀο¡ 0.25~0.5mg Á¤¸ÆÅõ¿©, ¾î¸°ÀÌ¿¡ 10~20mcg/kg)À» Åõ¿©ÇØ¾ß ÇÑ´Ù. ÀÌ ¾àÀ» ´Ù·® º¹¿ëÇÑ °æ¿ì À弼ôÀ» ÇÑ´Ù. »ð°ü ¹× ÀΰøÈ£Èí±â Ä¡·á´Â Áõ»óÀÌ¸Å¿ì ±¤¹üÀ§ÇÒ ¶§ Àû¿ëµÇ¾î¾ß ÇÑ´Ù. ÀûÀýÇÏ°Ô Ç÷Àå·®À» ´ëüÇϰí, »ê¤ý¿°±â¿Í ÀüÇØÁúÀ» ±³Á¤Çϰí ECG¸¦ ¸ð´ÏÅÍÇÑ´Ù. ¼¸Æ°ú ¹æ½ÇÂ÷´ÜÀÌ ³ªÅ¸³ª¸é ¼ºÀο¡°Ô ¾ÆÆ®·ÎÇÉ0.5~1.0mg(¾î¸°ÀÌ¿¡°Ô´Â 20~50 mcg/kg)À» Á¤¸ÆÁÖ»çÇϸç, ¹ÌÁÖ Áõ»ó¿¡ µû¶ó ¹Ýº¹Åõ¿©Çϰųª À̼ÒÇÁ·¹³¯¸° 0.05~0.1 mcg/kg/minÀ» Ãʱ⠿뷮À¸·Î Åõ¿©ÇÑ´Ù. ÁßÁõÀÇ °æ¿ì¿¡´Â Ãʱ⿡ ½É¹ÚÁ¶À²±â¸¦ »ç¿ëÇÑ´Ù. ÀúÇ÷¾Ð½Ã¿¡´Â ¼ö¾×À» Á¤¸ÆÁÖ»çÇÏ°í ¼ºÀο¡°Ô´Â 5ºÐµ¿¾È calcium glubionate (9mg Ca / ml)À» 20~30ml Á¤¸ÆÁÖ»çÇϰí(¾î¸°ÀÌ¿¡°Ô´Â 3~5 mg Ca/kg) ÇÊ¿äÇÑ °æ¿ì À̸¦ ¹Ýº¹Çϰųª Á¤¸ÆÁÖÀÔÇÑ´Ù. ¾Æµå·¹³¯¸°À̳ª µµÆÄ¹ÎÀÌ »ç¿ëµÉ ¼ö ÀÖÀ¸¸ç, ÁßÁõÀÇ °æ¿ì¿¡ ±Û·çÄ«°ïÀÌ »ç¿ëµÉ ¼ö ÀÖ´Ù. ¼øÈ¯Á¤Áö½Ã¿¡´Â ¸î ½Ã°£µ¿¾È Àΰø¼Ò»ý¼úÀÌ ÇÊ¿äÇÒ ¼ö ÀÖ´Ù. °æ·ÃÀÌ ÀÖ´Â °æ¿ì, µð¾ÆÁ¦ÆÊÀ» Åõ¿©ÇÑ´Ù
 
  | 
   
  
  
  
  		
  
  
   
    | º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ | 
    Â÷±¤ÇÑ ±â¹Ð¿ë±â, ½Ç¿Â(1-30¡É)º¸°ü | 
   
  	
  
  
    
   
    | ±âŸ | 
    º» Á¦ÀÇ Åõ¿© Áß¿¡ Çö±âÁõ°ú ÇǷΰ¨ÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ¿îÀüÀ̳ª ±â°è Á¶À۽ÿ¡´Â ÁÖÀÇÇÏ¿©¾ß ÇÑ´Ù.  | 
   
  
  
  
  
  
      							
 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¤º¸¿ä¾à | 
                 
	         
	       | 
	           	    
	     |  
	    | 
  
    µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
    
  
  
    
  
   |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ÄÚµå ¹× ºÐ·ùÁ¤º¸ | 
                 
	         
	       | 
	           	    
	     |  
	    | 	 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¦Ç°Á¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× | 
    
      
      
        
        646800460[A03805691]  
	    
	    Àú°¡¾à ´ëü Àμ¾Æ¼ºê Áö±Þ ´ë»ó
          [º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸] 
          
        
        
        
          
          
            \0 ¿ø/1Á¤(2020.02.01)(Ãֽžడ)
            \367 ¿ø/1Á¤(2017.02.01)(º¯°æÀü¾à°¡)
        
          
            
	 
  	   
  	   
       
      
       
       
     
      
      
     
      
    
    
      
     [»óº´ÄÚµåÁ¶È¸]
      
     [Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
    
     | 
   
  
  
   
    | Á¦Ç°¼º»ó | 
    
      ¿¬ºÐÈ«»öÀÇ ¿øÇü Çʸ§ÄÚÆÃÁ¤  
      
	  [Á¦ÇüÁ¤º¸ È®ÀÎ]
     |   
   
  
  
  
  
  
   
    | ´ëü°ü·Ã | 
    »ýµ¿¼º ½ÃÇè ¿Ï·á | 
                                    
  
  
  
  
  
  
  
   
    ´ëüÁ¶Á¦ Àμ¾Æ¼ºê  ǰ¸ñ | 
    ¾÷µ¥ÀÌÆ®±âÁØÀÏ:2009.03.15 [´ëüÁ¶Á¦ Àμ¾Æ¼ºê Áö±Þ´ë»ó ǰ¸ñÀÔ´Ï´Ù/Àû¿ëÀÏ:20041201/½Ä¾àû°ø°í1691¹ø] | 
   
  
  
  
   
    | Æ÷À塤À¯Åë´ÜÀ§ | 
    ÀÚ»çÆ÷Àå´ÜÀ§¿¡ µû¸§ | 
   
  
  
  
   
    | º¸°ü¹æ¹ý | 
    Â÷±¤ÇÑ ±â¹Ð¿ë±â, ½Ç¿Â(1-30¡É)º¸°ü | 
   
  
  
  
   
    µ¿ÀÏÁÖ¼ººÐÄÚµå  °Ë»ö¼øÀ§ | 
    
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
      
     | 
   
                                                          															
  
  
  
  
  
       
  
  
  
   
  |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | º¹¾àÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
   
    | LACTmed ¹Ù·Î°¡±â | 
    
      
        [¹Ù·Î°¡±â]
     | 
     
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
       
     | 
     
  
  
  
   
    | Ãà¾àº¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
       
  
  
   
    | º¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
                                                          															
  
   
  
  
   
    | ÀӺο¡´ëÇÑÅõ¿© | 
    
      
      
        
	      
	      
	        | *  | 
	        
	          ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù. 
	         | 
	         
	       
	       | 
	   
	  
	    |   | 
	   
	  
	    
	      FDA : Cµî±Þ 
				        	
					  
					
	   | 
	  
	  
	  
	     
	     
	     
	     
	     
	     
	   | 
	 
	
	  
	      
	      
	        | *  | 
	        
	          »ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
	         | 
	         
	      
	        | *  | 
	        
	          ¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
	         | 
	         
	       
	   | 
	 
       
     | 
   
  
  
  
   
    ½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
  	   
  
  	   
  
  	   
  
  
     
      | Pharmacokinetics | 
      
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
      
       |   
     
  
  
  
  
  
  
  	
  
  
  
   
    | º¹¾à¶óº§ | 
    
    
    
      | À̹ÌÁö | 
      º¹¾à¼³¸í | 
     
    
    
        | 
      ÀÓ»êºÎ ¶Ç´Â ÀӽŰèȹÁß º¹¿ë±ÝÁö | 
     
    
       | 
     
    
    
        | 
      º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. | 
     
    
       | 
     
    
    
        | 
      ¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. | 
     
    
       | 
     
    
     |  
    
      
	
	  
            | *  | 
	    º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. | 
	   
	  
            | *  | 
	    º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. | 
	   
	  
            | *  | 
	    ±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. | 
	   
	   
     |   
     | 
   
  	
  
  
  
   
    | º¸°ü»ó ÁÖÀÇ | 
    
      
    	
     | 
   
  
  
   
    | Á¶Á¦½Ã ÁÖÀÇ | 
    
      
    	
     | 
      
 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ½É»çÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	     |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | ÇмúÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
    | DUR (ÀǾàǰ»ç¿ëÆò°¡) | 
    º´¿ë±Ý±â :
     
	 °í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
	 
	  [»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]										
	  ¿¬·É´ë±Ý±â :
      °í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
      
       [¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
       
       
        
        
     | 
   
  
   
    | Mechanism of Action | 
    
       Felodipine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Felodipine is a calcium channel blocker. It reversibly competes with nitrendipine and/or other calcium channel blockers for dihydropyridine binding sites, blocks voltage-dependent calcium currents in vascular smooth muscle and cultured rabbit atrial cells, and blocks potassium-induced contracture of the rat portal vein. By blocking the calcium channels, felodipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes and results in a decrease of peripheral vascular resistance. 
     | 
   
  
   
    | Pharmacology | 
     
       Felodipine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Felodipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Felodipine is similar to other peripheral vasodilators. Felodipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes blocking the calcium channels. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload. 
     | 
   
  
   
    | Metabolism | 
    
       Felodipine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 3A4 (CYP3A4) 
     | 
   
  
   
    | Protein Binding | 
    
       Felodipine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 99% 
     | 
   
  
   
    | Half-life | 
    
       Felodipine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 14.1 hours 
     | 
   
  
   
    | Absorption | 
    
       Felodipine¿¡ ´ëÇÑ Absorption Á¤º¸ 15% 
     | 
   
  
   
    | Pharmacokinetics | 
    
       FelodipineÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
	- ÀÛ¿ë¹ßÇö½Ã°£ : 2-5½Ã°£
	
 - ÀÛ¿ëÁö¼Ó½Ã°£ : 16-24½Ã°£
	
 - Èí¼ö : 100%  ( absolute : ÃÊȸÅë°úÈ¿°ú·Î ÀÎÇÏ¿© 20%)
	
 - ´Ü¹é°áÇÕ : 99% ÀÌ»ó
	
 - ´ë»ç : °£¿¡¼ 99% ÀÌ»ó
	
 - ¹Ý°¨±â : 11-16½Ã°£
	
 - ¼Ò½Ç : ´ë»çü·Î¼ ´¢¸¦ ÅëÇØ ¹è¼³µÈ´Ù.
  
 
	 
	
     | 
   
  
   
    | Biotransformation | 
    
       Felodipine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic 
     | 
   
  
   
    | Toxicity | 
    
       Felodipine¿¡ ´ëÇÑ Toxicity Á¤º¸ Symptoms of overdose include excessive peripheral vasodilation with marked hypotension and possibly bradycardia. Oral rat LD50 is 1050 mg/kg. 
     | 
   
  
   
    | Drug Interactions | 
    
       Felodipine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Amobarbital	The barbiturate decreases the effect of felodipineAprobarbital	The barbiturate decreases the effect of felodipineButabarbital	The barbiturate decreases the effect of felodipineButalbital	The barbiturate decreases the effect of felodipineButethal	The barbiturate decreases the effect of felodipineCarbamazepine	Carbamazepine decreases the effect of felodipineDihydroquinidine barbiturate	The barbiturate decreases the effect of felodipineHeptabarbital	The barbiturate decreases the effect of felodipineHexobarbital	The barbiturate decreases the effect of felodipineMethohexital	The barbiturate decreases the effect of felodipineMethylphenobarbital	The barbiturate decreases the effect of felodipinePentobarbital	The barbiturate decreases the effect of felodipinePhenobarbital	The barbiturate decreases the effect of felodipinePrimidone	The barbiturate decreases the effect of felodipineQuinidine barbiturate	The barbiturate decreases the effect of felodipineSecobarbital	The barbiturate decreases the effect of felodipineTalbutal	The barbiturate decreases the effect of felodipineErythromycin	Erythromycin increases the effect of felodipineJosamycin	Erythromycin increases the effect of felodipineEthotoin	The hydantoin decreases the effect of felodipineFosphenytoin	The hydantoin decreases the effect of felodipineMephenytoin	The hydantoin decreases the effect of felodipinePhenytoin	The hydantoin decreases the effect of felodipineQuinupristin	This combination presents an increased risk of toxicityItraconazole	Itraconazole increases effect/toxicity of felodipineNelfinavir	Nelfinavir increases the effect and toxicity of felodipineOxcarbazepine	Oxcarbazepine decreases the levels of felodipineTacrolimus	Felodipine increases tacrolimus levels 
     | 
   
  
   
    CYP450  Drug Interaction | 
    
      [CYP450 TableÁ÷Á¢Á¶È¸] Felodipine¿¡ ´ëÇÑ P450 table
  SUBSTRATES 
CYP 3A4/3A5/3A7 
Macrolide antibiotics: 
clarithromycin 
erythromycin 
NOT azithromycin 
telithromycin 
Anti-arrhythmics: 
quinidine 
Benzodiazepines: 
alprazolam 
diazepam 
midazolam 
triazolam 
Immune Modulators: 
cyclosporine 
tacrolimus (FK506) 
HIV Protease Inhibitors: 
indinavir 
ritonavir 
saquinavir 
Prokinetic: 
cisapride 
Antihistamines: 
astemizole 
chlorpheniramine 
Calcium Channel Blockers: 
amlodipine 
diltiazem 
**felodipine** 
nifedipine 
nisoldipine 
nitrendipine 
verapamil 
HMG CoA Reductase Inhibitors: 
atorvastatin 
cerivastatin 
lovastatin 
NOT pravastatin 
simvastatin 
aripiprazole 
buspirone 
gleevec 
haloperidol (in part) 
methadone 
pimozide 
quinine 
NOT rosuvastatin 
sildenafil 
tamoxifen 
trazodone 
vincristine 
 INHIBITORS 
CYP 3A4/3A5/3A7 
HIV Protease Inhibitors: 
indinavir 
nelfinavir 
ritonavir 
amiodarone 
NOT azithromycin 
cimetidine 
clarithromycin 
diltiazem 
erythromycin 
fluvoxamine 
grapefruit juice 
itraconazole 
ketoconazole 
mibefradil 
nefazodone 
troleandomycin 
verapamil 
 INDUCERS 
CYP 3A4/3A5/3A7 
carbamazepine 
phenobarbital 
phenytoin 
rifabutin 
rifampin 
St. John's wort 
troglitazone 
 
     | 
   
  
   
    | Food Interaction | 
    
       Felodipine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take without regard to meals.Grapefruit and grapefruit juice should be avoided throughout treatment as grapefruit can significantly increase serum levels of this product. 
     | 
   
  
   
    | Drug Target | 
    
      
      [Drug Target]
     | 
   
  
   
    | Description | 
    
       Felodipine¿¡ ´ëÇÑ Description Á¤º¸ A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. [PubChem] 
     | 
   
  
   
    | Drug Category | 
    
       Felodipine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Arrhythmia AgentsAntiarrhythmic AgentsAntihypertensive AgentsCalcium Channel BlockersDihydropyridinesVasodilator Agents 
     | 
   
  
   
    | Smiles String Canonical | 
    
       Felodipine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC 
     | 
   
  
   
    | Smiles String Isomeric | 
    
       Felodipine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCOC(=O)C1=C(C)NC(C)=C([C@H]1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC 
     | 
   
  
   
    | InChI Identifier | 
    
       Felodipine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3 
     | 
   
  
   
    | Chemical IUPAC Name | 
    
       Felodipine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ O3-ethyl O5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
     | 
   
    
  |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | »ç¿ëÀÚÄÁÅÙÃ÷ | 
                             
	         
	       | 
	           	  
       |  
	     |  
	   
	     	
 
  | 
   
   
     | 
   
  
    
      
        
          
            
              - 
                ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-11-03
              
 
              - 
                
                º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
                
              
     
             
         |                 
       
     |       
          
                
                    
                       ¾Ë¸² | 
                       
                      »ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.  | 
                    
                    | 
               
      
      
                
                    
                       °æ°í | 
                     
                      µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù. 
                          Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â 
                          Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
                            ¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
                          ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
 | 
                    
                    | 
               
  
 
  
    ¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é 
    ¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
   
  The database contains the following fields: The generic name of each chemical For module A10 (liver enzyme composite module): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the number of active and marginally active scores for each compound at the five individual endpoints (see research article for full description of method) Number of endpoints at which each compound is marginally active (M) Number of endpoints at which each compound is active (A) For modules A11 to A15 (alkaline phosphatase increased, SGOT increased, SGPT increased, LDH increased, and GGT increased, respectively): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the RI and ADR values (see the research article for full description of method) Number of ADR reports for each compound, given as <4 or ¡Ã4 Reporting Index value for each compound, except where no shipping units were available (NSU) Group 1 comprises of compounds for which ADR data were available for the first five years of marketing, so when no ADR reports were listed during this period the compounds were evaluated as inactive. Group 2 comprises of compounds for which a 'steady state' period of ADR data were available (1992-1996). In cases where no ADR reports were filed during this period, the compounds were scored as 'NA' (data not available) since they may have had one or more ADR reports during their first five years of marketing which should not be negated by a lack of ADR reports during the steady-state period. FELODIPINE[GGT Increase][Composite Activity](Score)  I(Marginal)  0(Active)  0[Alkaline Phosphatase Increase](Activity Score)  I(Number of Rpts)  <4(Index value)  0.6[SGOT Increase](Activity Score)  I(Number of Rpts)  <4(Index value)  0.3[SGPT Increase](Activity Score)  I(Number of Rpts)  <4(Index value)  0.3[LDH Increase](Activity Score)  I(Number of Rpts)  <4(Index value)  0.3[GGT Increase](Activity Score)  I(Number of Rpts)  <4(Index value)  0.3
 
  º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
 
  
  |  
             
             | 
         
         
         | 
         |